Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Amortization of Deferred Charges (2016 - 2025)

Pediatrix Medical (MD) has disclosed Amortization of Deferred Charges for 11 consecutive years, with $237000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 5.58% to $237000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $935000.0, a 1.99% decrease, with the full-year FY2025 number at $935000.0, down 1.99% from a year prior.
  • Amortization of Deferred Charges was $237000.0 for Q4 2025 at Pediatrix Medical, down from $240000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.7 million in Q3 2021 to a low of $200000.0 in Q1 2024.
  • A 5-year average of $461400.0 and a median of $281000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 30.29% in 2021; the steepest drop was 73.6% in 2021.
  • Pediatrix Medical's Amortization of Deferred Charges stood at $815000.0 in 2021, then plummeted by 48.59% to $419000.0 in 2022, then crashed by 46.54% to $224000.0 in 2023, then increased by 12.05% to $251000.0 in 2024, then fell by 5.58% to $237000.0 in 2025.
  • Per Business Quant, the three most recent readings for MD's Amortization of Deferred Charges are $237000.0 (Q4 2025), $240000.0 (Q3 2025), and $228000.0 (Q2 2025).